18F-DOPA PET/CT in neuroblastoma: Comparison of conventional imaging with CT/MR

Egesta Lopci, Arnoldo Piccardo, Cristina Nanni, Vania Altrinetti, Alberto Garaventa, Andrea Pession, Angelina Cistaro, Arturo Chiti, Giampiero Villavecchia, Stefano Fanti

Research output: Contribution to journalArticle

Abstract

Aim: Role of 18F-DOPA PET/CT in neuroblastoma (NB) compared with CT/MR. Materials and Methods: In all, 21 patients (M:F = 14:7; mean age, 7.4 years) affected by advanced stage NB (III-IV) were prospectively enrolled. Overall, 37 paired 18F-DOPA PET and CT/MR scans were performed, and for each, we identified site and number of lesions. Standard of reference was based on a multidisciplinary assessment, including I-MIBG, selective biopsy, and clinical-instrumental monitoring. Both scan-based and a lesion-based analysis was performed, and for each modality, we calculated sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), and accuracy. Results: On the scan-based analysis, 18F-DOPA PET and CT/MR showed the following rates: sensitivity, specificity, NPV, PPV, and accuracy were 100%, 92.3%, 100%, 96%, and 97.3% versus 91.7%, 61.5%, 80%, 81.5%, and 81.1%, respectively (P = 0.014). Overall 179 findings were reported at imaging, of which 139 (77.7%) resulted true sites of disease at final outcome. On the lesion-based analysis, the 2 imaging modalities showed the following sensitivity, specificity, NPV, PPV, and accuracy rates: 90.6%, 90%, 73.5%, 96.9%, and 90.5% versus 47.5%, 27.5%, 13.1%, 69.5%, and 43% (P <0.00001). Conclusions: In our study, 18F-DOPA PET/CT results more accurate than CT/MR in advanced stage NB therefore should be taken into consideration for the diagnostic workup of these patients.

Original languageEnglish
JournalClinical Nuclear Medicine
Volume37
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Neuroblastoma
Sensitivity and Specificity
3-Iodobenzylguanidine
Biopsy

Keywords

  • F-DOPA, PET/CT
  • CT
  • MR
  • neuroblastoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

18F-DOPA PET/CT in neuroblastoma : Comparison of conventional imaging with CT/MR. / Lopci, Egesta; Piccardo, Arnoldo; Nanni, Cristina; Altrinetti, Vania; Garaventa, Alberto; Pession, Andrea; Cistaro, Angelina; Chiti, Arturo; Villavecchia, Giampiero; Fanti, Stefano.

In: Clinical Nuclear Medicine, Vol. 37, No. 4, 04.2012.

Research output: Contribution to journalArticle

Lopci, Egesta ; Piccardo, Arnoldo ; Nanni, Cristina ; Altrinetti, Vania ; Garaventa, Alberto ; Pession, Andrea ; Cistaro, Angelina ; Chiti, Arturo ; Villavecchia, Giampiero ; Fanti, Stefano. / 18F-DOPA PET/CT in neuroblastoma : Comparison of conventional imaging with CT/MR. In: Clinical Nuclear Medicine. 2012 ; Vol. 37, No. 4.
@article{dbe95a8739294c009b4957c3c1d4c43d,
title = "18F-DOPA PET/CT in neuroblastoma: Comparison of conventional imaging with CT/MR",
abstract = "Aim: Role of 18F-DOPA PET/CT in neuroblastoma (NB) compared with CT/MR. Materials and Methods: In all, 21 patients (M:F = 14:7; mean age, 7.4 years) affected by advanced stage NB (III-IV) were prospectively enrolled. Overall, 37 paired 18F-DOPA PET and CT/MR scans were performed, and for each, we identified site and number of lesions. Standard of reference was based on a multidisciplinary assessment, including I-MIBG, selective biopsy, and clinical-instrumental monitoring. Both scan-based and a lesion-based analysis was performed, and for each modality, we calculated sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), and accuracy. Results: On the scan-based analysis, 18F-DOPA PET and CT/MR showed the following rates: sensitivity, specificity, NPV, PPV, and accuracy were 100{\%}, 92.3{\%}, 100{\%}, 96{\%}, and 97.3{\%} versus 91.7{\%}, 61.5{\%}, 80{\%}, 81.5{\%}, and 81.1{\%}, respectively (P = 0.014). Overall 179 findings were reported at imaging, of which 139 (77.7{\%}) resulted true sites of disease at final outcome. On the lesion-based analysis, the 2 imaging modalities showed the following sensitivity, specificity, NPV, PPV, and accuracy rates: 90.6{\%}, 90{\%}, 73.5{\%}, 96.9{\%}, and 90.5{\%} versus 47.5{\%}, 27.5{\%}, 13.1{\%}, 69.5{\%}, and 43{\%} (P <0.00001). Conclusions: In our study, 18F-DOPA PET/CT results more accurate than CT/MR in advanced stage NB therefore should be taken into consideration for the diagnostic workup of these patients.",
keywords = "F-DOPA, PET/CT, CT, MR, neuroblastoma",
author = "Egesta Lopci and Arnoldo Piccardo and Cristina Nanni and Vania Altrinetti and Alberto Garaventa and Andrea Pession and Angelina Cistaro and Arturo Chiti and Giampiero Villavecchia and Stefano Fanti",
year = "2012",
month = "4",
doi = "10.1097/RLU.0b013e3182485172",
language = "English",
volume = "37",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - 18F-DOPA PET/CT in neuroblastoma

T2 - Comparison of conventional imaging with CT/MR

AU - Lopci, Egesta

AU - Piccardo, Arnoldo

AU - Nanni, Cristina

AU - Altrinetti, Vania

AU - Garaventa, Alberto

AU - Pession, Andrea

AU - Cistaro, Angelina

AU - Chiti, Arturo

AU - Villavecchia, Giampiero

AU - Fanti, Stefano

PY - 2012/4

Y1 - 2012/4

N2 - Aim: Role of 18F-DOPA PET/CT in neuroblastoma (NB) compared with CT/MR. Materials and Methods: In all, 21 patients (M:F = 14:7; mean age, 7.4 years) affected by advanced stage NB (III-IV) were prospectively enrolled. Overall, 37 paired 18F-DOPA PET and CT/MR scans were performed, and for each, we identified site and number of lesions. Standard of reference was based on a multidisciplinary assessment, including I-MIBG, selective biopsy, and clinical-instrumental monitoring. Both scan-based and a lesion-based analysis was performed, and for each modality, we calculated sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), and accuracy. Results: On the scan-based analysis, 18F-DOPA PET and CT/MR showed the following rates: sensitivity, specificity, NPV, PPV, and accuracy were 100%, 92.3%, 100%, 96%, and 97.3% versus 91.7%, 61.5%, 80%, 81.5%, and 81.1%, respectively (P = 0.014). Overall 179 findings were reported at imaging, of which 139 (77.7%) resulted true sites of disease at final outcome. On the lesion-based analysis, the 2 imaging modalities showed the following sensitivity, specificity, NPV, PPV, and accuracy rates: 90.6%, 90%, 73.5%, 96.9%, and 90.5% versus 47.5%, 27.5%, 13.1%, 69.5%, and 43% (P <0.00001). Conclusions: In our study, 18F-DOPA PET/CT results more accurate than CT/MR in advanced stage NB therefore should be taken into consideration for the diagnostic workup of these patients.

AB - Aim: Role of 18F-DOPA PET/CT in neuroblastoma (NB) compared with CT/MR. Materials and Methods: In all, 21 patients (M:F = 14:7; mean age, 7.4 years) affected by advanced stage NB (III-IV) were prospectively enrolled. Overall, 37 paired 18F-DOPA PET and CT/MR scans were performed, and for each, we identified site and number of lesions. Standard of reference was based on a multidisciplinary assessment, including I-MIBG, selective biopsy, and clinical-instrumental monitoring. Both scan-based and a lesion-based analysis was performed, and for each modality, we calculated sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), and accuracy. Results: On the scan-based analysis, 18F-DOPA PET and CT/MR showed the following rates: sensitivity, specificity, NPV, PPV, and accuracy were 100%, 92.3%, 100%, 96%, and 97.3% versus 91.7%, 61.5%, 80%, 81.5%, and 81.1%, respectively (P = 0.014). Overall 179 findings were reported at imaging, of which 139 (77.7%) resulted true sites of disease at final outcome. On the lesion-based analysis, the 2 imaging modalities showed the following sensitivity, specificity, NPV, PPV, and accuracy rates: 90.6%, 90%, 73.5%, 96.9%, and 90.5% versus 47.5%, 27.5%, 13.1%, 69.5%, and 43% (P <0.00001). Conclusions: In our study, 18F-DOPA PET/CT results more accurate than CT/MR in advanced stage NB therefore should be taken into consideration for the diagnostic workup of these patients.

KW - F-DOPA, PET/CT

KW - CT

KW - MR

KW - neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=84858147946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858147946&partnerID=8YFLogxK

U2 - 10.1097/RLU.0b013e3182485172

DO - 10.1097/RLU.0b013e3182485172

M3 - Article

C2 - 22391727

AN - SCOPUS:84858147946

VL - 37

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 4

ER -